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CONTROLLING THE PRODUCT QUALITY ATTRIBUTES OF A COMPLEX RECOMBINANT PROTEIN IN A 
HIGH CELL DENSITY PERFUSION BIOREACTOR PROCESS 
 




Perfusion processes for biopharmaceutical manufacturing have gained significant attention over the last few 
years as a means to significantly improve productivity and product quality over conventional fed batch 
processes.  A few cases have recently been reported that higher cell densities (100-200E6 vc/mL) and higher 
productivities (2-4 g/L/day) were successfully achieved with perfusion processes. At Shire, perfusion platforms 
have been established and multiple perfusion processes for the production of complex and heavily glycosylated 
proteins have been developed and scaled up to clinical and commercial scales successfully. In this 
presentation, we will discuss our experience and challenges encountered during the development of a high cell 
density perfusion process for a complex and heavily glycosylated recombinant protein and our approaches to 
overcome these challenges. 
 
A baseline perfusion bioreactor process at 50-60E6 vc/mL utilizing an ATF retention device was initially 
established but some of the product quality attributes could not be maintained robustly when the cell density 
was further increased to 80-90E6 vc/mL. The impact of nutrient availability, inhibitor accumulation & product 
retention were investigated to understand the product quality differences at different cell densities. The overall 
strategy and approach to control and improve product quality attributes will be discussed.  
  
 
